{
  "abstract": "Last 28 March 2025, the European Commission decided not to renew the conditional marketing authorisation for Translarna (ataluren) in Duchenne’s disease due to lack of efficacy after 11 years in the market.",
  "authors": [
    {
      "affiliations": [
        "Innovation and Organization Unit, Navarre Health Service, Pamplona, Navarre, Spain",
        "IdiSNA, Pamplona, Navarre, Spain"
      ],
      "name": "Juan Erviti"
    },
    {
      "affiliations": [
        "Innovation and Organization Unit, Navarre Health Service, Pamplona, Navarre, Spain",
        "IdiSNA, Pamplona, Navarre, Spain"
      ],
      "name": "Luis Carlos Saiz"
    },
    {
      "affiliations": [
        "Innovation and Organization Unit, Navarre Health Service, Pamplona, Navarre, Spain",
        "IdiSNA, Pamplona, Navarre, Spain"
      ],
      "name": "Marta Gutiérrez-Valencia"
    }
  ],
  "title": "Ataluren for Duchenne: how politics and social pressure undermined evidence-based decisions",
  "uid": "622b24e4-60a1-5d59-8d6c-d15b5128f924"
}